Anavex Life Sciences Corp. (NASDAQ:AVXL) saw strong trading volume on Wednesday . 5,949,096 shares were traded during trading, an increase of 284% from the previous session’s volume of 1,550,940 shares.The stock last traded at $4.43 and had previously closed at $7.49.

Several equities analysts recently weighed in on the company. Maxim Group set a $15.00 target price on Anavex Life Sciences Corp. and gave the company a “buy” rating in a research report on Wednesday. FBR & Co reiterated an “outperform” rating and set a $10.00 target price on shares of Anavex Life Sciences Corp. in a research report on Tuesday. Finally, Zacks Investment Research downgraded Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th.

The company’s market cap is $159.27 million. The firm’s 50-day moving average is $5.71 and its 200-day moving average is $4.89.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. Analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.